Surmodics (SRDX) Q3 EPS Turns Positive

Surmodics (NASDAQ:SRDX), a medical device technology firm known for its vascular intervention products and performance coatings, released results for Q3 FY2025 on August 8, 2025. The core news was a beat on both the top (GAAP revenue) and bottom (non-GAAP EPS) lines. Non-GAAP earnings per share reached $0.06 versus an expected loss of $(0.18), and GAAP revenue came in at $29.6 million, well above the $28.05 million consensus. While overall GAAP revenue dropped 3% from the prior-year period, Key product lines like thrombectomy devices and diagnostics showed growth that helped partially offset larger declines elsewhere. In context, the quarter reflected stabilization in the core business and sharp cost controls amid ongoing merger uncertainty. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report. Surmodics specializes in technologies for the medical device industry. The company develops products that treat vascular disease—such as drug-coated balloons (DCBs) that deliver medication directly into blood vessels—and provides advanced coatings to improve the performance of a wide range of medical devices. Its business model rests on commercializing proprietary devices, earning royalties and license fees from coating technologies, and forging strategic partnerships with leading health-care companies like Abbott and Medtronic.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool